- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
35 result(s) found for: COVID-19.
Displaying page 1 of 2.
EudraCT Number: 2021-001103-32 | Sponsor Protocol Number: HEPCOViVac | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: The HEPCOViVac Registry - Immunological response in patients with liver disease vaccinated against COVID-19 | ||
Medical condition: Cirrhotic chronic liver disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-004166-37 | Sponsor Protocol Number: 100424 | Start Date*: 2023-05-02 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric oxygenation for patients with orthostatic dysregulation (postural orthostatic tachycardia) in Long- COVID. Prospectively randomized cross- over study. | ||
Medical condition: Multiorgan symptoms after COVID-19 infection (Long COVID) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003277-55 | Sponsor Protocol Number: CAR-CF | Start Date*: 2021-09-01 | ||||||||||||||||
Sponsor Name:Medical University of Innsbruck, University Clinic for Pediatrics III | ||||||||||||||||||
Full Title: COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF | ||||||||||||||||||
Medical condition: COVID-19 vaccine Antibody response from natural infection or after vaccination in patients with Cystic Fibrosis (CF) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002984-23 | Sponsor Protocol Number: 33-391ex20/21 | Start Date*: 2021-08-01 |
Sponsor Name:Medical University of Graz | ||
Full Title: Retrospective quantification of anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in patients treated with peritoneal dialysis | ||
Medical condition: Chronic peritoneal dialysis patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001126-21 | Sponsor Protocol Number: 100423 | Start Date*: 2021-04-14 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric Oxygenation for patients with post-COVID-19 sequelae. Pilot study. | ||
Medical condition: Multiorgan symptoms after COVID-19 infection (Long COVID) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000291-11 | Sponsor Protocol Number: IMRES | Start Date*: 2021-05-30 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19) | |||||||||||||
Medical condition: Vaccination against SARS-CoV-2 in immunocompromised patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002927-39 | Sponsor Protocol Number: BOOST_TX/RESCUE_TX | Start Date*: 2021-06-13 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C... | ||
Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001682-12 | Sponsor Protocol Number: MYOFLAME-19 | Start Date*: 2023-06-16 | ||||||||||||||||
Sponsor Name:Goethe University Frankfurt | ||||||||||||||||||
Full Title: Randomised placebo controlled clinical trial of efficacy of MYOcardial protection in patients with postacute inFLAMmatory cardiac involvEment due to COVID-19 (MYOFLAME-19) | ||||||||||||||||||
Medical condition: Inflammatory cardiovascular involvement due to COVID-19, defined by Cardiovascular magnetic resonance imaging | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001329-30 | Sponsor Protocol Number: 2020P000787 | Start Date*: 2020-04-09 |
Sponsor Name:Massachussetts General Hospital | ||
Full Title: Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19 | ||
Medical condition: ARDS caused by COVID-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-004118-12 | Sponsor Protocol Number: NVX_PCV20 | Start Date*: 2023-03-05 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Safety and immunogenicity of concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a four-arm, double-blind, non-inferiority trial | ||
Medical condition: Vaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumo... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002789-42 | Sponsor Protocol Number: IMMUNE | Start Date*: 2021-07-08 |
Sponsor Name:Medizinische Universität Innsbruck | ||
Full Title: Analysis and characterization of the immune response after influenza, SARS-CoV-2 and pneumococcal vaccinations (IMMUNE Study) | ||
Medical condition: Analysis and characterization of the immune response after influenza, SARS-CoV-2 and pneumococcal vaccinations (IMMUNE Study) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003452-14 | Sponsor Protocol Number: SBC007C401 | Start Date*: 2023-05-02 | |||||||||||
Sponsor Name:Berlin Cures GmbH | |||||||||||||
Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability... | |||||||||||||
Medical condition: long Covid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) AT (Ongoing) FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006951-32 | Sponsor Protocol Number: REP0321 | Start Date*: 2022-04-05 | |||||||||||
Sponsor Name:Dompé farmaceutici s.p.a. | |||||||||||||
Full Title: Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multina... | |||||||||||||
Medical condition: COVID-19 and other community-acquired pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) IT (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000623-13 | Sponsor Protocol Number: VIR-7831-5008 | Start Date*: 2021-07-29 | ||||||||||||||||
Sponsor Name:Vir Biotechnology, Inc. | ||||||||||||||||||
Full Title: A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the... | ||||||||||||||||||
Medical condition: Mild/moderate COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) AT (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001172-15 | Sponsor Protocol Number: APN01-01-COVID19 | Start Date*: 2020-04-08 |
Sponsor Name:APEIRON Biologics AG | ||
Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 | ||
Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2022-000736-37 | Sponsor Protocol Number: 1001 | Start Date*: 2022-08-12 | ||||||||||||||||
Sponsor Name:Biotest AG | ||||||||||||||||||
Full Title: A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneu... | ||||||||||||||||||
Medical condition: non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) HU (Completed) AT (Ongoing) BE (Ongoing) LV (Ongoing) LT (Ongoing) PT (Ongoing) SK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002501-53 | Sponsor Protocol Number: D5180C00018 | Start Date*: 2019-05-29 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Se... | |||||||||||||
Medical condition: Severe Uncontrolled Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) AT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003302-50 | Sponsor Protocol Number: ARGX-117-2002 | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicit... | |||||||||||||
Medical condition: Multifocal Motor Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Ongoing) IT (Ongoing) PL (Ongoing) AT (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000498-15 | Sponsor Protocol Number: RXC007/0002 | Start Date*: 2022-10-04 | |||||||||||
Sponsor Name:Redx Pharma plc | |||||||||||||
Full Title: A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients with Idiopathic... | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) CZ (Ongoing) ES (Ongoing) HU (Prematurely Ended) AT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001411-25 | Sponsor Protocol Number: XPORT-COV-1001 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||
Full Title: A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection | |||||||||||||
Medical condition: Severe COVID-19 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.